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Abstract
Background: Developmental regression (DR) occurs in about one-third of chil-
dren with Autism Spectrum Disorder (ASD) yet it is poorly understood. Cur-
rent evidence suggests that mitochondrial function in not normal in many
children with ASD. However, the relationship between mitochondrial function
and DR has not been well-studied in ASD. Methods: This cross-sectional study
of 32 children, 2 to 8 years old with ASD, with (n = 11) and without (n = 12)
DR, and non-ASD controls (n = 9) compared mitochondrial respiration and
mtDNA damage and copy number between groups and their relation to stan-
dardized measures of ASD severity. Results: Individuals with ASD demon-
strated lower ND1, ND4, and CYTB copy number (Ps < 0.01) as compared to
controls. Children with ASD and DR had higher maximal oxygen consumption
rate (Ps < 0.02), maximal respiratory capacity (P < 0.05), and reserve capacity
(P = 0.01) than those with ASD without DR. Coupling Efficiency and Maximal
Respiratory Capacity were associated with disruptive behaviors but these rela-
tionships were different for those with and without DR. Higher ND1 copy
number was associated with better behavior. Conclusions: This study suggests
that individuals with ASD and DR may represent a unique metabolic endophe-
notype with distinct abnormalities in respiratory function that may put their
mitochondria in a state of vulnerability. This may allow physiological stress to
trigger mitochondrial decompensation as is seen clinically as DR. Since mito-
chondrial function was found to be related to ASD symptoms, the mitochon-
dria could be a potential target for novel therapeutics. Additionally, identifying
those with vulnerable mitochondrial before DR could result in prevention of
ASD.
Introduction
Autism Spectrum Disorder (ASD) affects 1 in 59 chil-
dren.1 Despite intensive research, the etiologies of ASD
are still unclear. One area of promising research is the
link between mitochondrial function and ASD. Mitochon-
drial function is important in tissues with high-energy
demand, notably the brain, gastrointestinal tract, and
immune system – all systems which are commonly dys-
functional in individuals with ASD.2,3
An important distinction when discussing abnormali-
ties of mitochondrial physiology is the difference between
mitochondrial disease and mitochondrial dysfunction.
Meta-analysis has demonstrated that 5% of children with
ASD can be diagnosed with the very circumscribed diag-
nosis of mitochondrial disease, which is defined by very
low electron transport chain (ETC) complex activity or a
clear genetic defect.4 In contrast, the same meta-analysis
found that 30%-50% of individuals with ASD demon-
strate biomarkers of mitochondrial dysfunction.4,5 Other
studies suggest that up to 80% of individuals with ASD
show abnormal ETC activity in lymphocytes and granulo-
cytes6,7 as well as postmortem brain.8 Thus, it is hypothe-
sized that individual with ASD have unique changes in
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mitochondrial function that may be distinct from classi-
cally defined mitochondrial disease.4,9 For example, rather
than significant decreases is ETC complex activity, indi-
viduals with ASD have been found to have significant ele-
vations in ETC complex activity in multiple tissues.8,10–14
In a model of mitochondrial dysfunction in ASD, a subset
of lymphoblastoid cell lines (LCLs) from boys with ASD
have been shown to have elevated respiratory rates and
found to be sensitive to physiological stress.15,16
About 32% of children with ASD undergo an enigmatic
developmental regression (DR) during the second year of
life.17,18 Following apparently normal development, DR
involves loss of the child’s previously acquired milestones
followed by the emergence of ASD symptoms.17,19–23 DR
most often appears clinically after childhood illness, often
with fever.24,25 Atypical DR (e.g., multiple regressions)26
and DR accompanied by fever25 has been associated with
mitochondrial disease in ASD. Despite this association,
most studies studying mitochondria function in relation
to ASD have not closely examined DR.
Our goal was to study the relationship between DR
and mitochondrial bioenergetics in children with ASD.
We hypothesized that DR is triggered in a subset of chil-
dren with ASD due to underlying abnormalities in mito-
chondrial function. We hypothesize that children with
ASD and DR have marginal but adequate mitochondrial
function until a trigger increases physiological stress that
overwhelms the capacity of mitochondria to function,
resulting in clinically observed DR. Marginal mitochon-
drial function could be represented by very low mito-
chondrial activity, as seen in mitochondrial disease, but
we believe that marginal mitochondrial function could
also be represented by very high mitochondrial activity, as
seen in the LCL model since such elevated respiratory
rates could represent a state in which the mitochondria is
close to its maximum ability to function, making mito-
chondria sensitivity to physiological stress.9,15,16 To this
end, this study examined mitochondrial function and
mitochondrial DNA (mtDNA) damage and copy number
in peripheral blood mononuclear cells (PBMCs) from
three age-matched groups of children: those with ASD,
with and without DR, and non-ASD controls.
Materials and Methods
Participants
The protocol was approved by the University of Mas-
sachusetts Medical Center, Worcester, Institutional
Review Board. Following informed written consent of
the parents and assent by children who were able, 10–
15cc of blood was drawn by venipuncture. The diagnosis
of ASD and history of DR were confirmed by a single
clinician (AWZ) from extensive medical history, exami-
nation and review of medical records. Symptoms of
ASD were measured for each child with ASD using the
clinician-rated Ohio Autism Clinical Impression Scale–
Severity (OACIS-S)27 and parent-completed Aberrant
Behavior Checklist (ABC)28 and Social Responsiveness
Scale-2 (SRS).29
Bioenergetic measurements
PBMCs were isolated within 2 h of phlebotomy using
Histopaque 1077 protocol. PBMCs were counted, sus-
pended in culture medium (90% FBS/10% DMSO) and
frozen at 80°C in a specialized Mr Frosty cryofreeze
container (Thermo Fisher Scientific, Waltham, MA).
PBMCs were transferred to LN3 liquid nitrogen chamber
within 24 h and transferred to the University of Arizona
laboratory for analysis on dry ice by overnight carrier
within 12 months of collection. Upon receipt, they were
stored in LN3 liquid nitrogen chamber until Seahorse
assay. PBMC average (standard deviation; range) viability
was 48% (16%, 22%–65%), 57% (12%; 26%–80%), and
44% (19%, 27%–70) for ASD/No-DR, ASD/DR, and
CNT groups, respectively, and was not significantly differ-
ent between groups. In our experience, a viability of 20%
or greater provides reliable Seahorse measurements.
PBMC’s were resuspended in RPMI medium (Life tech-
nologies, Gibco, Grand Island, NY) supplemented with
1 mmol/L pyruvate, 2 mmol/L glutamax, and 25 mmol/L
glucose, warmed to 37°C and pH adjusted to 7.4 prior to
cell suspension. XFe96 plates (Seahorse Bioscience, Biller-
ica, MA) were prepared by adding 25 lL of 50 lg/mL
Poly-D-lysine (EMD Millipore, Billerica, MA) for 2 h,
washing with 250 lL sterile water and drying in a laminar
flow hood overnight prior to seeding with 600 k viable
PBMCs per well. All available PMBCs were utilized result-
ing in 1–8 wells per participant, thus allowing for several
replicates per participant. One ASD/DR and two CNT
participants only had one well, so their data were not
used. However, inclusion of their data did not change
any results significantly.
After seeding, the plates were spun with slow accelera-
tion (4 on a scale of 9) to a maximum of 100 g for
2 min and then allowed to stop with zero braking
(Eppendorf Model 5810R Centrifuge). The plate orienta-
tion was reversed, and the plate was spun again to 100 g
in the same fashion. Prior to Seahorse assay, XFe96 wells
were visualized using an inverted microscope to ensure
that PBMCs were evenly distributed in a single layer and
viability of the cells was confirmed by trypan blue exclu-
sion.
Mitochondrial bioenergetics were assessed using the
Seahorse XFe96 extracellular flux analyzer by measuring
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oxygen consumption rate (OCR) and deriving bioenergetic
measures. OCR is a fundamental measure of mitochon-
drial function and reflects coupled mitochondrial respira-
tion as well as uncoupled consumption of oxygen which is
used to regulate reactive oxygen species at the inner mito-
chondrial membrane.30–33 Figure 1 depicts the typical Sea-
horse flux analyzer assay and its various parameters.
The assay is a 4-step process which monitors OCR in
response to various reagents that activate or inhibit the
ETC complexes.
1. Baseline OCR: Baseline OCR is measured before intro-
ducing any reagents.
2. OCR after oligomycin: Oligomycin, a complex V inhibi-
tor, shuts down the production of ATP so the OCR
related to ATP production can be determined.
3. Maximal OCR: Carbonyl cyanide-p-trifluoromethoxy-
phenyl-hydrazone is used to collapse the mitochondrial
inner membrane gradient, inducing the mitochondria to
function at its maximum extent possible.
4. Nonmitochondrial OCR: Antimycin A and Rotenone
are added to shut down ETC complex activity to mea-
sure OCR from non-ETC processes.
The production of protons is also monitored and pro-
vides an additional measurement:
1. Extracellular acidification rate = Rate of free protons
production in the microchamber at baseline conditions.
The following measures are derived from the above
measurements:
1. ATP-linked respiration: The fraction of basal OCR that
is attributed to ATP production
ATP-Linked respiration ¼ baseline OCR
OCR after oligomycin
2. Proton-leak respiration: The amount of basal OCR that
is associated with protons leaking through the inner
mitochondrial membrane in order to control oxidative
stress
Proton-leak respiration ¼ OCR after oligomycin
 non-mitochondrial OCR
3. Maximal respiratory capacity: The maximum respira-
tory rate of the ETC. This parameter is thought to be
Figure 1. Depiction of a typical Seahorse assay and various mitochondrial respiratory parameters. Oxygen consumption rate (OCR) is measured to
determine mitochondrial activity. Three OCRs are measured over an 18 min period to determine mitochondrial activity for each segment of the
assay. Regents are added to determine parameters of mitochondrial activity. Basal Respiration is the difference between baseline OCR and
nonmitochondrial OCR. Oligomycin, which is a complex V inhibitor, is added to determine the portion of Basal Respiration that is ATP-Linked
Respiration and Proton-Leak Respiration. Carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP), a protonophore, is added to collapse the
inner membrane gradient, driving the mitochondria to respire at its maximal rate. This determines Maximal Respiratory Capacity. Antimycin A and
Rotenone, complex III and I inhibitors, stop mitochondrial respiration in order to determine the nonmitochondrial respiration. Reserve Capacity is
the difference between Basal Respiration and Maximal Respiratory Capacity.
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sensitive to deficits in mitochondrial biogenesis,
mtDNA damage and/or inhibition of ETC function.
Maximal respiratory capacity¼maximalOCR
 non-mitochondrialOCR
4. Reserve capacity: The amount of extra ATP that can be
produced by oxidative phosphorylation when there is
a sudden increase in energy demand. This parameter is
an index of mitochondrial health; when it becomes
negative, the mitochondrion is unhealthy leading
toward apoptosis.
Reserve capacity ¼ maximal OCR baseline OCR
5. Coupling efficiency: The amount of ATP made per
atom of oxygen consumed. This parameter provides a
measure of how much of the mitochondria’s total res-
piratory rate is contributing to the production of
energy and how much is wasted to control oxidative
stress.
Coupling efficiency ¼ ATP
 linked respiration=ðbaseline OCR
Non  mitochondrial OCRÞ
 100:
6. Bioenergetic health index (BHI): The BHI combines
multiple measures for mitochondrial respiration into
one index which represents overall mitochondrial
function and health.34 The index represents the mito-
chondrial energy production corrected for oxygen con-
sumption by sources which do not produce energy.
The BHI has been developed using the Seahorse plat-
form to measure mitochondrial function in peripheral
immune cells34 and is proposed as a biomarker of
bioenergetic health.35–38
BHI ¼ ðreserve capacity  ATP
 linked respirationÞ=ðproton leak respiration
 non - mitochondrial OCR)
7. Proton efflux rate: A measure of proton flux corrected
for important assay factors. Since Proton Efflux Rate is
a linear transformation of the Extracellular Acidifica-
tion Rate, only the Proton Efflux Rate is analyzed.
Proton efflux rate ¼ extracellular acidification rate
 in situ buffering capacity
 geometric volume of the plate well:
Derived measures were calculated for each well. Mea-
surements were averaged across wells for each participant
to obtain one value per participant. Wells with nonphysi-
ological ATP-Linked Respiration and Proton-Leak Respi-
ration values (<2 pMol/min) were not used.
Mitochondrial DNA (mtDNA) analysis
Genomic DNA was isolated from PBMCs from 11 ASD
(7 ASD/DR, 4 ASD/No-DR) and 7 CNT participants
using QIAamp DNA Mini Kit (QIAGEN, Germantown,
MD). The DNA concentration was measured by the spec-
trophotometer Nano Drop 2000C (Thermo Scientific).
Toyobo ThunderbirdTM SYBR qPCR master mix was used
with standard block protocol in BIO-RAD CFX96 Real-
Time System.
The human RT-PCR mtDNA damage analysis kit
(Detroit R&D, Inc.) measures the amount of damage to
long (8.1–8.8 kb) mtDNA pieces. A higher product repre-
sents less mtDNA damage. The PCR DNA volume (2 µL)
product from the qPCR was optimized by serially diluting
(10-to-10,000 fold) with the nuclease free water. The
quantification of the RT-PCR products was calculated
against the standard curve using threshold cycle (Ct)
value and the DNA concentration (log scale) of each of
the 8.8 kb mtDNA standards. Samples were run in dupli-
cate and averaged.
The NovaQUANTTM Human Mitochondrial-to-Nuclear
DNA ratio Kit (EMD Millipore Corporation) measured
quantities of two nuclear (BECN and NEB) and two
mitochondrial (ND1 and ND6) genes. Positive (human
wt) and negative (rho zero) controls were included for
mitochondrial targets. A ‘no template control’ NTC using
the DNase/RNase free water was also used. The abun-
dance of each gene was estimated from the corresponding
cycle threshold (Ct) value. The Ct differences (ΔCt)
between ND1/BECN and ND6/NEB was used to estimate
copy number (2ΔCt). The average ΔCt between BECN and
NEB was 0.34 (SD = 0.24) which suggests technical accu-
racy (<1.0).
Copy number of NADH Dehydrogenase 4 (ND4) and
Cytochrome B (CYTB) genes were also measured using
the pyruvate kinase (PK) gene as the nuclear gene refer-
ence. DNA primer sequences reported by Gu et al.39 were
synthesized by Integrated DNA Technologies Inc (Coral-
ville, IA). A Toyobo ThunderbirdTM SYBR qPCR master
mix (Toyobo Life Sciences, Japan) with standard block
protocol in BIO-RAD CFX96 Real Time System (Bio-Rad
Laboratory Inc, Hercules, CA) was used to denature at
95°C for 10 min followed by 40 cycles at 95°C for 15 sec
and 60°C for 1 min. Each 20 µL RT-PCR reaction mix-
ture contained 9ng of isolated genomic DNA, 0.4 µmol/L
forward primers 0.4 µmol/L reverse primers, and 10 µL
2xSYBR qPCR master mix. A ‘no template control’ NTC
using the DNase/RNase free water was also included. The
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Ct differences (ΔCt) between ND4/PK and CYTB/PK were
used to calculate copy number (2ΔCt).
Statistical analysis
Two one-way Analysis of Variance (ANOVA) were used
to compare OCR rates, derived parameters, and mtDNA
measurements across groups (ASD vs. CNT and ASD/DR
vs. ASD/No-DR) using SAS (Version 14.1, SAS Institute,
Cary, NC). Linear regression models (SAS procedure
glimmix) was used to analyze the relationship between
behavioral measures and derived bioenergetic and
mtDNA parameters including only ASD participants. The
regression models included the factor of DR and its inter-
action. Because of the large number of behavioral mea-
sures (23 measures), the Bonferroni correction was used
to set the P-value cut-off (0.05/23 = 0.002). To better
understand relationships between mitochondrial measure-
ments and behavior in regression models which demon-
strated significant DR interactions, correlations were
performed between the behavioral measures and the
derived parameters for the DR groups separately.
Results
Participant characteristics
Table 1 and Table S1 provide participant characteristics.
There were no statistically significant differences between
the CNT, ASD/DR, and ASD/No-DR groups. There were
few small but significant differences between behavioral
measures across ASD groups.
Mitochondrial respiration
As seen in Figure 2A and Table S2, the ASD group had a
statistically significant higher Maximal OCR as compared
to the CNT group with this effect driven by the signifi-
cantly higher Maximal OCR values for the ASD/DR
group as compared to the ASD/No-DR group:
• At 59.8 min, the ASD/DR group (145.8  70.1) had
78% higher OCR than the ASD/no-DR group
(81.8  49.9) and 118% higher OCR than CNT group
(66.8  56.4).
Table 1. Baseline summary of demographic and clinical characteristics.
Variable ASD/DR ASD/No-DR Controls P-value
Number of participants 11 12 9 –
Gender (female) 1/11 (9%) 3/12 (25%) 4/9 (44%)
Age (years)  SD 7.13  1.7 5.14  1.5 6.60  2.1 0.06
OACIS-S scores  SD
General level of autism 4.8  0.9 5.3  0.9 – 0.20
Social interaction 4.8  0.9 5.5  0.8 – 0.07
Aberrant behaviors 4.5  0.9 4.8  0.9 – 0.40
Repetitive behaviors 4.5  1.6 4.6  1.1 – 0.80
Verbal communication 4.8  1.1 5.6  1.2 – 0.08
Non-verbal communication 4.4  0.8 5.2  0.8 – 0.02*
Hyperactivity/inattention 4.6  1.1 5.2  1.0 – 0.20
Anxiety 4.2  1.6 3.9  1.1 – 0.70
Sensory sensitivities 4.2  0.8 4.9  0.8 – 0.04*
Restricted/narrow interests 4.2  1.6 4.5  0.7 – 0.50
Aberrant behavior checklist  SD
Total score 48.6  24.7 65.1  25.3 – 0.10
Subscale irritability 11.8  6.6 12.8  7.4 – 0.80
Subscale lethargy 8.8  6.9 14.2  5.9 – 0.06
Subscale stereotypy 7.4  4.7 9.1  5.6 – 0.50
Subscale hyperactivity 16.1  10.5 25.2  9.6 – 0.04*
Subscale inappropriate speech 4.5  2.5 3.8  3.0 – 0.60
Social responsiveness scale  SD
Total raw score 106.8  21.6 111.7  23.2 – 0.60
Awareness raw score 14.1  2.9 13.4  2.9 – 0.50
Cognition raw score 20.2  3.6 21.2  5.1 – 0.60
Communication raw score 36.8  9.0 37  9.5 – 0.90
Motor skills raw score 15.3  5 18.9  3.6 – 0.08
Repetitive behaviors raw score 20.3  5.9 21.4  5.8 – 0.70
SCI raw score 86.5  17.7 90.3  18.1 – 0.60
*Significant P-values are shown in bold.
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• At 66.3 min, the ASD/DR group (111.7  54.2) had
78% higher OCR than the ASD/no-DR group
(62.7  37.7) and 103% higher OCR than CNT group
(55.0  44.8).
• At 72.8 min, the ASD/DR group (93.5  46.5) had
75% higher OCR than the ASD/no-DR group
(53.5  31.9) and 97% higher OCR than CNT group
(47.5  39.4).
Figure 2. Mitochondrial Oxygen Consumption Rate (OCR) as measured by the Seahorse analyzer using the assay shown in Figure 1. (A)
Comparison of the Seahorse curves for the three comparison groups: Autism Spectrum Disorder (ASD) without developmental regression (ASD/No-
DR, n = 12), ASD with developmental regression (ASD/DR, n = 11) and non-ASD control group (Non-ASD, n = 9). Analysis of variance demonstrated
that the ASD/DR group has a significantly higher Maximal OCR as compared to the ASD/No-DR group. (B) Seahorse profiles for twin boys, one with
and one without developmental regression. These data suggest that maximal OCR is higher for the twin with developmental regression.
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To examine this in more detail, a pair of 7-year-old
male fraternal twins, both diagnosed with ASD but only
one with DR were examined in more detail. As seen in
Figure 2B, Maximal OCR is obviously much higher in
Twin A with ASD/DR compared to Twin B with ASD/
No-DR.
Respiratory parameters
Figure 3 demonstrates the derived respiratory parameters
separately for the clinical group (ASD vs. CNT) and
regression status (DR vs. No-DR). One of the most obvi-
ous findings is the variability in respiratory parameters
for the ASD groups as compared to the control group.
There was no significant difference between the average
ASD and CNT values.
The two groups of participants with ASD demonstrated
differences in respiratory parameters depending on
whether nor not they had a history of DR. Those with
DR demonstrated significantly higher Maximal Respira-
tory Capacity [F(1,21) = 4.71, P < 0.05; Fig. 3C] and
Reserve Capacity [F(1,21) = 7.41, P = 0.01; Fig. 3D].
mtDNA analysis
Overall mtDNA damage was not significantly different
between ASD and CNT participants but was lower
(higher amount of 8.8kb mtDNA segments) in ASD/No-
DR participants compared to ASD/DR participants [F
(1,9) = 6.40, P < 0.05] (Fig. 3H). The relative number of
ND1 [F(1,17) = 9.86, P < 0.01; Fig. 3I], ND4 [F
(1,17) = 13.72, P < 0.01; Fig. 3J] and CYTB [F
Figure 3. Differences in derived parameters and mitochondrial DNA (mtDNA) across Autism Spectrum Disorder (ASD) and developmental
regression (DR) groups. Each individual participant data point is plotted with the mean and standard error of the group to the left of the
individual points. Participants with ASD demonstrated lower (I) ND1, (J) ND4, and (L) CYTB copy number as compared to control participants.
Those children with ASD and a history of DR demonstrated higher (C) Maximal Respiratory Capacity and (D) Reserve Capacity as compared to
those children with ASD but no history of DR. Those children with ASD without a history of DR demonstrated less (H) mtDNA damage as
compared to those children with ASD who had a history of DR.
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(1,17) = 8.64, P < 0.01; Fig. 3L] gene copies was signifi-
cantly reduced in ASD participants as compared to the
CNT participants. The copy number of ND6 (Fig. 3L),
the only gene tested which resides on the mtDNA light-
chain, was not different with respect to participant group
or DR status.
Associations between behavioral measures
and mitochondrial function
As seen in Figure 4A–C the relationship between behavior
and derived respiratory parameters was different depend-
ing on the history of DR for the OACIS-S subscales of
Aberrant Behavior and Maximal Respiratory Capacity [F
(1,16) = 14.85, P = 0.001; Fig. 4A] and Hyperactivity and
Coupling Efficiency [F(1,16) = 17.69, P < 0.001; Fig. 4B]
and for the ABC Stereotyped Behavior subscale and Cou-
pling Efficiency [F(1,16) = 17.42, P < 0.001; Fig. 4C]. In
general, for those without a history of DR higher Maxi-
mal Respiratory Capacity or Coupling Efficiency was asso-
ciated with less severe behaviors while for those with a
history of DR higher Maximal Respiratory Capacity or
Coupling Efficiency was associated with more severe
behaviors. In general the relationships between behavior
and mitochondrial respiration were stronger for the ASD
participants without a history of DR. Higher ND1 copy
number was associated with better (i.e., lower) OACIS-S
subscales of Repetitive Behavior [F(1,5) = 45.66,
P = 0.001] (Fig. 4D).
Discussion
DR is an important feature that affects about one-third of
children with ASD.17 To better understand the signifi-
cance of mitochondrial function in DR, we examined
bioenergetics using the Seahorse XF96 analyzer in live
immune cells derived from controls and children with
ASD, both with and without DR. We have previously
documented abnormal mitochondrial function in PBMCs
using the Seahorse XF96 in siblings with ASD and genetic
abnormalities40 and in children with ASD and immune
abnormalities.41 Our data demonstrate that differences in
Figure 4. Relationship between behavioral measures and measures of mitochondrial function. The relationship between aberrant behavior and
respiratory measures of Coupling Efficiency and Maximal Reserve Capacity was different for those with and without a history of developmental
regression (DR). For those individuals with ASD without a history of DR (ASD/No-DR), higher respiratory values were associated with better
behavior whereas the relationship was opposite for those with ASD and a history of DR (ASD/DR). Greater ND1 copy number was associated with
better ASD behavior.
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mitochondrial respiration are found in children with ASD
depending on a history of DR, and that mitochondrial
respiration and mtDNA ND1 copy number are associated
with ASD symptoms, particularly in those without a his-
tory of DR. This suggests that variations in mitochondrial
function are important in understanding the underlying
physiological abnormalities in children with ASD, espe-
cially regarding their clinical characteristics.
Relationship between ASD and
mitochondrial DNA
Data from this study suggests that young children with
ASD, regardless of whether they demonstrated DR or not,
have significantly lower copy number of important mtDNA
genes associated with ETC function, including ND1 and
CYTB. A large study (n = 122) of leukocytes in individuals
with ASD and intellectual disability found a decrease in
ND1 copy number associated with ASD.42 While a small
study (n = 14) of ASD brain tissue found a relative increase
in ND1 copy number,39 the same study found deletions in
the same genes and decreased ETC activity.39 Additionally,
other studies have found deletions in CYTB6,7 which is
another gene found to have a decreased copy number in
this study. Higher ND1 copy number was related to less
aberrant behavior. Since this study found a reduction in
ND1 copy number relative to CNT, this relationship could
suggest more normal ND1 copy number, and thus possibly
more normal ETC Complex 1 function, could be related to
less disruptive behavior.
ASD/No-DR participants demonstrated less mtDNA
damage compared to ASD/DR. Although mtDNA damage
has not been examined in ASD in the past, other studies
have noted an increased mtDNA copy number in leuko-
cytes6,7,43–45 and buccal mucosa.46 An increase in overall
mtDNA content is believed to be a compensatory reaction
that maintains adequate wild-type mtDNA in the face of
high levels of oxidative stress which itself can damage and
cause deletions in mtDNA.7 Thus, it is possible that these
data suggest that ASD/No-DR individuals are better able to
regulate oxidative stress, thereby reducing mtDNA damage.
Relationship between developmental
regression and mitochondrial function
The ASD/DR group demonstrated higher respiration rates
as compared to the ASD/No-DR group. First, the maxi-
mal OCR of the ASD/DR group was nearly double that of
the ASD/No-DR group. In a pair of fraternal twins, the
twin with DR had more than twice the peak OCR com-
pared to his twin without DR. Second, Maximal Respira-
tory Capacity and Reserve Capacity were higher in the
ASD/DR group as compared to ASD/No-DR group.
Rose et al.16 hypothesized that higher than normal
Reserve Capacity may be a protective adaptation in
response to environmental stressors while Bennuri et al47
showed that prolonged exposure to low-levels of oxidative
stress could induce this increase in baseline Reserve
Capacity. However, this increase in Reserve Capacity is
associated with a sensitivity to oxidative stress such that
lower levels of reactive oxygen species are needed to
deplete Reserve Capacity, leading to mitochondrial dys-
function. Thus, we believe that the subset of LCLs with
increased Reserve Capacity are a good model for DR.
Previous reports have linked mitochondrial disease in
children with25,26,48 and without49–51 ASD to DR, espe-
cially with an associated trigger. This is the first study to
provide evidence for a unique type of mitochondrial dys-
function, that is most likely distinct from mitochondrial
disease, to be related to ASD with DR. Thus, children
with ASD and DR make up an important subset of chil-
dren with ASD that require further careful study of their
mitochondria. Interestingly, previous in vitro studies have
shown that N-acetylcysteine (NAC) protects LCLs with
high respiratory rates from losing Reserve Capacity under
physiological stress,52 suggesting a potential prophylactic
treatment for patients with vulnerable mitochondria to
prevent developmental regression and possibly prevent
ASD or at least mitigate symptom severity.
Limitations
Our study is not without limitations. We have a small
sample size due to the difficulty in confirming DR and
age matching to children with ASD without DR and con-
trols. Indeed, our novel findings need to be validated in a
larger sample. The BHI needs to be studied in a larger
sample where the relative weights of different components
of the BHI can be examined. Nevertheless, our data pro-
vide evidence that our patients with ASD and DR may
have impaired mitochondrial function.
Conclusions
In this study we found that specific parameters of mito-
chondrial function vary with ASD symptomatology
including behavior and history of developmental regres-
sion. This suggests that mitochondria have a direct effect
on the severity of ASD symptoms and opens the possibil-
ity that interventions targeting the mitochondria could
have a role in the prevention of developmental regression
and treating ASD symptomatology. Additionally, these
important clinical factors, especially developmental regres-
sion, needs to be considered when recruiting individuals
with ASD to study mitochondrial function as the
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participant characteristics will directly affect the mito-
chondrial function of the sample.
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